Press Releases

Biocon Secures 10-Year Supply Contract for Pertuzumab in Brazil

Biocon has secured a 10-year PDP allocation for pertuzumab in Brazil through a partnership with Bahiafarma and Bionovis, covering around 70% of the country’s public-sector demand. The agreement combines long-term supply with phased local production, supporting affordable cancer treatment access and strengthening Brazil’s domestic biopharmaceutical capabilities.

CluePoints Launches Three AI-Led Clinical Data Review Capabilities, Co-Innovated with a Top 10 Pharmaceutical Company

Intelligent Query Detection, Medical & Safety Review and Intelligent Medical Coding are now generally available, extending CluePoints' science-first approach from RBQM into clinical data review. The partner will join CluePoints live at SCDM 2026 to celebrate the launch.

Yourgene Health Insight DPYD Assay Achieves IVDR Accreditation

Comprehensive pharmacogenetic testing solution aligned with latest clinical guidance to support informed chemotherapy treatment decisions

MIB Agents Now Accepting Letters of Intent for 2027 OutSmarting Osteosarcoma Research Grants

MIB Agents, a leading pediatric osteosarcoma nonprofit dedicated to Making It Better for its community of patients, families, medical professionals, researchers and industry partners, is accepting letters of intent (LOI) starting on Wednesday, September 9, for its annual OutSmarting Osteosarcoma research grant program.

Inceptua Acquires SupplyRx to Enhance Pharmacy Services for Clinical Trials

Inceptua Group today announced the acquisition of SupplyRx to enhance pharmacy services for clinical trials.

Integrion Automation Builds on Its Medical Device Capabilities to Support Validated, Traceable Production

Integrion Automation provides validated, traceable automation solutions for medical device manufacturers, helping improve quality, compliance, and flexibility in regulated production environments. Its GAMP 5-based approach, validation services, advanced inspection and assembly technologies, and lifecycle support help manufacturers reduce risk while maintaining audit-ready operations.

Researchers Gain Faster Access to Complex DNA as Integrated DNA Technologies and Ansa Biotechnologies Expand Ordering Platform

Integrated DNA Technologies (IDT) and Ansa Biotechnologies expand partnership, making it easier for researchers to access longer, more complex DNA.

Inceptua Group Selected to Manage TikoMed’s Named Patient Program for Investigational Therapy ILB® in Amyotrophic Lateral Sclerosis (ALS)

Inceptua and TikoMed have announced the launch of a Named Patient Program for TikoMed’s investigational drug, ILB®, for eligible patients with Amyotrophic Lateral Sclerosis.

Symbiosis strengthens commercial team with appointment of Jay Chima

Allegheny Health Network and The START Center for Cancer Research Announce Strategic Collaboration to Expand Patient Access to Early-Phase Cancer Trials

New START site to be established within AHN Cancer Center will integrate novel oncology research therapies closer to patients across Western Pennsylvania.

Prescient completes integration of Uptake and Dolon under single global brand

Axplora's sustainability strategy substantiated by SBTi as company accelerates action across its manufacturing network

CPHI launches new Sustainability Summit as pharma faces growing pressure to deliver sustainability goals

Philips selects Blue Spark for continuous temperature monitoring in new connected care strategy

As advances in oncology, cell and gene therapy, and other complex treatments increasingly move care beyond traditional inpatient settings, the ability to continuously monitor patients for early signs of complications is becoming increasingly important. Philips announced a new strategy to expand its open patient monitoring ecosystem through collaborations with select wearable and out-of-hospital technology companies -- including Blue Spark Technologies, which was selected for its best-in-class continuous core body temperature monitoring technology. Blue Spark's TempTraq® wearable patch provides continuous core body temperature monitoring and has been clinically tested in more than 30 studies. Research has demonstrated its ability to detect fevers earlier than routine intermittent temperature monitoring -- an important distinction for patient or clinical trial populations where subtle temperature changes can provide an early warning of infection, inflammation, treatment-related complications, or clinical deterioration.

ECI’s Product & Packaging Testing Laboratory Achieves ISO/IEC 17025 Accreditation

ECI announced today that its Product & Packaging Testing Laboratory, located in the Coyol Free Zone in Costa Rica, has achieved ISO/IEC 17025:2017 accreditation from A2LA for technical competence in mechanical testing.

Sanofi’s MenQuadfi Wins EU Approval for Infants from Six Weeks Against Meningococcal Disease

Sanofi’s MenQuadfi has received European Commission approval for use in infants from six weeks of age against invasive meningococcal disease caused by serogroups A, C, W and Y. The expanded indication is supported by the MET58 pivotal study and clinical data involving more than 6,000 infants across 11 countries. The approval provides EU healthcare professionals with another option for early protection against a rapidly progressing and potentially fatal infection.

CellCarta Adds Tempus to CDx Commercialization Lab Network

CellCarta today announced a strategic collaboration with Tempus AI, Inc. (NASDAQ: TEM).

Headlands Research Expands Pacific Northwest Presence with New Clinical Research Site in Bellingham, Washington

Led by a board-certified psychiatrist and 2025 APA Fellow, Headlands Research's new purpose-built site gives sponsors access to more than 615,000 participants in an untapped CNS research market

Verista Announces Appointment of Michael Laferrera as Chief Executive Officer

Verista names seasoned healthcare and pharma services leader as CEO to drive strategic growth, innovation, and operational excellence.

TrialAssure® ANONYMIZE® Selected by the European Medicines Agency as Official Anonymisation Tool

TrialAssure® announced today that its ANONYMIZE® platform has been selected by the European Medicines Agency (EMA) as an official anonymisation tool used within the Agency.